MA32150B1 - Inhibiteurs heterocycliques de la stearoyl-coa desaturase - Google Patents

Inhibiteurs heterocycliques de la stearoyl-coa desaturase

Info

Publication number
MA32150B1
MA32150B1 MA33156A MA33156A MA32150B1 MA 32150 B1 MA32150 B1 MA 32150B1 MA 33156 A MA33156 A MA 33156A MA 33156 A MA33156 A MA 33156A MA 32150 B1 MA32150 B1 MA 32150B1
Authority
MA
Morocco
Prior art keywords
stearoyl
coa desaturase
heterocyclic inhibitors
heterocyclic
derivatives
Prior art date
Application number
MA33156A
Other languages
Arabic (ar)
English (en)
Inventor
Sultan Chowdhury
Natalie Dales
Julia Fonarev
Jianmin Fu
Duanjie Hou
Qi Jia
Vishnumurthy Kodumuru
Natalia Pokrovskaia
Shaoyi Sun
Zaihui Zhang
Original Assignee
Novartis Ag
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40740143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32150(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Xenon Pharmaceuticals Inc filed Critical Novartis Ag
Publication of MA32150B1 publication Critical patent/MA32150B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des dérivés hétérocycliques représentés par la formule (i) qui modulent l'activité de la stéaroyl-coa désaturase. L'invention concerne également des procédés d'utilisation des dérivés qui modulent l'activité de la stéaroyl-coa désaturase et des compositions pharmaceutiques comprenant ces dérivés.
MA33156A 2008-02-20 2010-09-09 Inhibiteurs heterocycliques de la stearoyl-coa desaturase MA32150B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3013708P 2008-02-20 2008-02-20
PCT/EP2009/051926 WO2009103739A1 (fr) 2008-02-20 2009-02-18 Inhibiteurs hétérocycliques de la stéaroyl-coa désaturase

Publications (1)

Publication Number Publication Date
MA32150B1 true MA32150B1 (fr) 2011-03-01

Family

ID=40740143

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33156A MA32150B1 (fr) 2008-02-20 2010-09-09 Inhibiteurs heterocycliques de la stearoyl-coa desaturase

Country Status (28)

Country Link
US (2) US8049016B2 (fr)
EP (1) EP2245029B1 (fr)
JP (2) JP5507474B2 (fr)
KR (1) KR101584826B1 (fr)
CN (1) CN102007123B (fr)
AR (1) AR070429A1 (fr)
AU (1) AU2009216769A1 (fr)
BR (1) BRPI0907826A2 (fr)
CA (1) CA2715947C (fr)
CL (1) CL2009000381A1 (fr)
CO (1) CO6290655A2 (fr)
CR (1) CR11629A (fr)
CU (1) CU23890B1 (fr)
EA (1) EA022797B1 (fr)
EC (1) ECSP10010411A (fr)
HN (1) HN2010001647A (fr)
IL (1) IL207578A (fr)
JO (1) JO3014B1 (fr)
MA (1) MA32150B1 (fr)
MX (1) MX2010009158A (fr)
MY (1) MY156317A (fr)
NZ (1) NZ587350A (fr)
PE (1) PE20091473A1 (fr)
SV (1) SV2010003650A (fr)
TW (1) TWI457338B (fr)
UA (1) UA105000C2 (fr)
WO (1) WO2009103739A1 (fr)
ZA (1) ZA201005725B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101535303B (zh) 2006-08-15 2012-07-18 诺瓦提斯公司 适合用于治疗与升高的脂质水平有关的疾病的杂环化合物
CN101595105B (zh) * 2006-12-20 2013-01-23 诺瓦提斯公司 作为scd抑制剂的2-取代的5元杂环化合物
WO2009103739A1 (fr) 2008-02-20 2009-08-27 Novartis Ag Inhibiteurs hétérocycliques de la stéaroyl-coa désaturase
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
BR112012007509A2 (pt) * 2009-10-01 2016-11-22 Novartis Ag derivados pirazóis que modulam estearoil-coa dessaturase
AR091022A1 (es) * 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
US9173883B2 (en) 2012-05-21 2015-11-03 Novartis Ag Ring-substituted N-pyridinyl amides as kinase inhibitors
EP3511332A4 (fr) * 2016-09-08 2020-03-25 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nouveau dérivé de 2-acylaminothiazole, son procédé de préparation et son utilisation
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
EA201991650A1 (ru) 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
CA3083000A1 (fr) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Composes et utilisations de ces composes
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
CN114222732B (zh) * 2019-10-28 2023-04-04 南京明德新药研发有限公司 一种尿酸促排剂及其合成方法和其在医药上的应用
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
AU2020407664A1 (en) * 2019-12-20 2022-08-18 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
GB202012969D0 (en) * 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058617A (en) 1972-10-04 1977-11-15 Ciba-Geigy Corporation Imidazoles and pharmaceutical composition
CH590267A5 (fr) * 1972-10-04 1977-07-29 Ciba Geigy Ag
IL44282A (en) 1974-02-25 1979-01-31 Ciba Geigy Ag 1-(1-alkyl-4(5)nitro-imidazol-2-yl)-2-oxo-tetrahydroimidazole derivatives, their manufacture and pharmaceutical compositions containing them
DE69821132T2 (de) 1997-10-27 2004-10-21 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
EP1205478A4 (fr) 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd INHIBITEURS DE p38MAP KINASE
WO2001074811A2 (fr) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Composes de 1,3-thiazole substitues, production et utilisation desdits composes
EP1354603A1 (fr) 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Co-prescriptions
CA2450400A1 (fr) 2001-06-11 2002-12-19 Takeda Chemical Industries, Ltd. Compositions medicinales
US20090192191A1 (en) 2004-01-09 2009-07-30 Braj Bhushan Lohray Substituted hydroxamic acid derivatives as tnf inhibitors
EP1621539A1 (fr) 2004-07-27 2006-02-01 Aventis Pharma S.A. Dérivées d'urée cyclique substitués par un heterocycle, leur prépration et leur utilisation pharmaceutique comee inhibiteurs de kinases
US7829712B2 (en) * 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
EP1807085B1 (fr) * 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et leur utilisation en tant qu'agents thérapeutiques
AU2006343359A1 (en) * 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2007143597A2 (fr) 2006-06-05 2007-12-13 Novartis Ag Composés organiques
CN101535303B (zh) * 2006-08-15 2012-07-18 诺瓦提斯公司 适合用于治疗与升高的脂质水平有关的疾病的杂环化合物
JP2010501567A (ja) * 2006-08-24 2010-01-21 ノバルティス アクチエンゲゼルシャフト 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物
KR20090053923A (ko) * 2006-09-22 2009-05-28 노파르티스 아게 헤테로시클릭 유기 화합물
GB0621452D0 (en) * 2006-10-27 2006-12-06 Ucl Business Plc Therapy for liver disease
CN101595105B (zh) * 2006-12-20 2013-01-23 诺瓦提斯公司 作为scd抑制剂的2-取代的5元杂环化合物
EP2241567A4 (fr) * 2008-02-13 2011-11-09 Eisai R&D Man Co Ltd Dérivé de bicycloamine
WO2009103739A1 (fr) 2008-02-20 2009-08-27 Novartis Ag Inhibiteurs hétérocycliques de la stéaroyl-coa désaturase
EP2307379A2 (fr) 2008-06-27 2011-04-13 Novartis AG Composés organiques

Also Published As

Publication number Publication date
CR11629A (es) 2010-11-16
MY156317A (en) 2016-02-15
US20120014906A1 (en) 2012-01-19
EA201001315A1 (ru) 2011-06-30
US8318949B2 (en) 2012-11-27
CA2715947C (fr) 2016-10-25
JP5813162B2 (ja) 2015-11-17
EA022797B1 (ru) 2016-03-31
KR20100117677A (ko) 2010-11-03
PE20091473A1 (es) 2009-10-23
CU23890B1 (es) 2013-04-19
CL2009000381A1 (es) 2010-09-10
CU20100170A7 (es) 2011-10-31
TWI457338B (zh) 2014-10-21
UA105000C2 (uk) 2014-04-10
JP5507474B2 (ja) 2014-05-28
JO3014B1 (ar) 2016-09-05
HK1144808A1 (en) 2011-03-11
HN2010001647A (es) 2013-11-11
CA2715947A1 (fr) 2009-08-27
CN102007123A (zh) 2011-04-06
MX2010009158A (es) 2010-09-24
AR070429A1 (es) 2010-04-07
ZA201005725B (en) 2011-04-28
SV2010003650A (es) 2011-07-05
IL207578A0 (en) 2010-12-30
CO6290655A2 (es) 2011-06-20
ECSP10010411A (es) 2010-09-30
US8049016B2 (en) 2011-11-01
KR101584826B1 (ko) 2016-01-18
NZ587350A (en) 2012-07-27
JP2014132025A (ja) 2014-07-17
BRPI0907826A2 (pt) 2019-12-10
EP2245029A1 (fr) 2010-11-03
EP2245029B1 (fr) 2015-04-15
CN102007123B (zh) 2014-04-30
IL207578A (en) 2014-11-30
TW200942534A (en) 2009-10-16
AU2009216769A1 (en) 2009-08-27
JP2011512384A (ja) 2011-04-21
WO2009103739A1 (fr) 2009-08-27
US20090264444A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
MA30655B1 (fr) Composes organiques.
MX2009003080A (es) Compuestos organicos heterociclicos.
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MX2009006728A (es) Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd.
DK2207770T3 (da) 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
EA201100049A1 (ru) Органические соединения
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
WO2007143597A3 (fr) Composés organiques
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
MA29785B1 (fr) Agents permettant de prevenir et de traiter des troubles entrainant la modulation des recepteurs ryr
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA200970156A1 (ru) Пиридизиноновые производные
MA31683B1 (fr) Composes et procedes pour moduler fxr
WO2008074824A3 (fr) Composés
MA33693B1 (fr) Dérivés de pyrazole qui modulent la stéroyl-coa désaturase
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
WO2007081808A3 (fr) Composes et derives pour le traitement d’etats medicaux par modulation de l’activite de la lipase hormono-sensible
ATE465151T1 (de) 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren
TN2010000378A1 (en) Heterocyclic inhibitors of stearoyl-coa desaturase
EA200801420A1 (ru) Фармацевтическое средство для лечения уретеролитиаза